Preparing for change

What are the pros and cons of opting-out my European patents?

Factors to consider

There is no one-size-fits all when deciding on whether or not to opt-out some or all of your European patents.

  • What is the strength of the assessment of the validity of the patent?
  • What is the value of the patent to the business?
  • How widely have you validated the patent? Have you maintained a broad territorial scope of protection?
  • Does the patent protect a key commercial product or is it defensive?
  • What size patent portfolio do you have, are their multiple layers of protection for your technology or a single “key” patent
  • Does the patent cover core product, platform or method technology or secondary patents?
  • Does the company rely on the patent(s) to attract investment or licensing revenue?
  • What is the nature of the licensing arrangements – exclusive licence versus lots of non-exclusive licences
  • Is there any complexity around the ownership of the patent?
  • Would the effort of identifying the correct ownership (or getting the owners to agree) of the patent be disproportionate to the value of the patent?
  • Do you operate in a litigious industry or are disputes in the patents court rare?
  • Are you aware of any third parties seeking to challenge the patent? For example, has the patent been opposed?
  • Do you have infringements or infringers across multiple UPC countries?

We are seeing different industries having different approaches. This in part depends on how litigious (or not) their industry is, the company’s appetite for risk and willingness to spend time and money on diligence around establishing ownership.

What are the benefits of leaving your European patents within the UPC system?

  • Now the UPC is live, it has non-exclusive jurisdiction over European patents that are in force in participating EU Member States. This means that both the UPC and competent national courts will have jurisdiction over those EPs that have not been opted-out. This allows patentees some flexibility to choose whether to enforce in the national courts or to enforce the bundle of EP national patents in a single infringement action before the UPC.
  • If you do not file an application to opt-out then the time and costs required to manage any due diligence exercise to determine the ownership position and file the opt-out are minimised.
  • Some patentees are choosing to leave at least some of their European patents within the UPC’s jurisdiction in order to gain some experience with the UPC system and influence the development of its case law.
  • An action before the UPC is heard by a panel of UPC Judges in a specified division but the Judgment has effect across all UPC countries where the patent is in force. This common, supranational court addresses the complaint that the current European patent system is fragmented.
  • It is the intention that actions filed with the UPC will be docketed strictly with the court rendering its Judgment within 12 months of issue. This is significantly faster for infringement proceedings than many of the national patent courts in EU Member States.
  • The UPC system means that it should be possible to prevent infringement across multiple jurisdictions in a single action.
  • The UPC may also allow patentees to capture infringement where parties working together infringe different elements of the claim in different jurisdictions
  • Depending on the development of the UPC’s case law, it may offer more favourable judicial interpretation on certain legal issues, e.g., selection inventions or the doctrine of equivalents.

What are the reasons for filing an opt-out to exclude the jurisdiction of the UPC?

  • The primary reason for filing an opt-out is to avoid the risk of the central revocation of the patent before the UPC. This is particularly the case where the Court is untried and untested so it is not possible to predict the outcome of actions reliably.
  • It is the intention that actions filed with the UPC will be docketed strictly with the court rendering its Judgment within 12 months of issue. This is significantly faster for revocation proceedings than many of the national patent courts in EU Member States and the central post-grant opposition proceedings available before the EPO.
  • Although more expensive and not as far reaching as EPO opposition proceeding, the central revocation can be brought at any time during the lifetime of the patent, including before or after the expiry of the 9-month opposition deadline, while the EPO opposition is ongoing and after it has concluded.
  • Opting-out maintains the status quo and a challenger would need to pursue a central opposition and/or bring multiple revocation actions before the national courts.
  • Provided that there have been no national proceedings relating to the patent before the courts of the participating EU Member States (referred to as “lock in”) then the patentee can file an application to withdraw the opt-out.
  • Where the ownership position is relatively straightforward, the time and costs associated with filing an opt-out are relatively minimal.
The Unitary Patent

What is the Unified Patent Court?

The UPC is a new common patents court with exclusive jurisdiction in respect of litigation (validity and infringement) for all EP(UPs) and non-exclusive jurisdiction over EPs validated in R-MS.

What is a UP?

The prosecution of European Patents will continue as before. At grant a European Patent (“EP”) will create a bundle of national rights but a new UP “designation” will become available.

Preparing for change

The Unified Patent Court (UPC) and a new “unitary patent” or “European patent with unitary effect” (UP) are likely to become a reality in the second half of 2022.

How do I opt-out of the UPC?

When the UPC comes into force, all existing and future European patents that are granted and validated in R-MS territories will become subject to the jurisdiction of the court.

Latest updates

Romania will become 18th country to participate in the UPC and UP - EPO announce possibility to delay the registration of unitary effect

From 1 September 2024 Romania will become the 18th country to participate in the UPC following ratification of the UPC Agreement. This means that any Unitary Patents registered on or …

Read article

Opinion Piece: Unitary Patent and Unified Patent Court in Ireland

Intellectual Property (IP) is a core part of any business and particularly is a vital part of the strategic toolkit for any business that creates value through innovation and constant …

Read article

First order to preserve evidence in the Paris Local Division of the UPC secured

HGF Partners Rachel Fetches, Richard Jenkins and IP Solicitor Christie Batty and its valued co-counsel Schertenleib Avocats Denis Schertenleib and Marc Lauzeral are pleased to have secured the first order …

Read article

UPC and Forum Shopping – Rule 17.3

Order of the classifications listed on the front of a patent and why it matters? On 1 June 2023, ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE lodged a statement of revocation of …

Read article
Event - 5th, 7th, 21st September 2023

Second Seminar in Salzburg, Dresden and Hamburg

HGF is organising a German-speaking seminar series in Salzburg, Dresden, and Hamburg. Dates September 5, 2023 at 17:30 – Dresden September 7, 2023 at 17:30 – Hamburg – CANCELLED September …

Event details

The UPC has opened its doors! See the latest updates and advice on the UPC here.

The European patent system has had the biggest change in a generation – on 1 June 2023 the Unified Patent Court (UPC) and a new “unitary patent” or “European patent …

Read article

A new dawn for European patents and patent litigation - 1 June 2023

Just as the UPC’s sunrise phase has ended, a new dawn is breaking for European patents and patent litigation.  After many years of anticipation, the Unified Patent Court (UPC) and …

Read article

EU Draft legislation on SPCs released

On 27 April 2023 the EU published 4 draft proposals regarding SPCs. Two of these proposals are completely new and propose the creation of Unitary SPCs: COM(2023)222 for medicinal product …

Read article